Medigus: Polyrizon Innovative Technology Demonstrated it may Prevent Allergic Reaction Caused by Common Allergens
November 01 2021 - 9:25AM
Medigus Ltd. (Nasdaq: MDGS), a technology company engaged in
advanced medical solutions, innovative internet technologies and
electric vehicle and charging solutions, today announced that
Polyrizon Ltd. (35.86%), informed Medigus that its pre-clinical
data demonstrated a potential to prevent allergic reaction induced
by house dust mites (HDM) and Timothy grass pollen allergens and
may also prevent respiratory tract allergy reactions caused by
other allergens.
Data from Polyrizon’s cell-culture study,
demonstrates that its Capture and Contain (C&C™) innovative
product, PL-14, has the potential to reduce the inflammatory
response while challenging the host cells with group 1 allergens
from Dermatophagoides pteronyssinus (Der p1) and pollen major
allergen (PhlP1) from Timothy grass, which is a common perennial
grass native to most of Europe. House dust mites are microscopic,
insect-like pests that generate some of the most common indoor
substances—or allergens—that can trigger allergic reactions such as
rhinitis, asthma and atopic dermatitis, expressed with running
nose, itchy eyes, and skin itching in many people.
Grass pollen allergy is one of the most common
allergies worldwide and can trigger of allergic rhinitis (hay
fever) and asthma symptoms. Pollen seasons can last for several
months and exposure is difficult to avoid.
Polyrizon tested a few prototypes of its C&C
platform as a shield against Der p1 and PhlP1 allergens. In these
studies, the lead product candidate, PL14, prevents the interaction
of the allergen with the host cell, as expressed with reduced
secretion of the chemokine cytokine IL-8, an important inducer of
allergic reactions.
Polyrizon’s lead product candidate, PL-14, has
been designed to protect the nasal cavity and the respiratory tract
creating an innate immune response by creating a physical barrier.
This barrier may prevent allergens from reaching the upper
respiratory epithelial cells and may decrease the inflammatory
response that leads to allergic reactions.
Recent pre-clinical studies by Polyrizon
demonstrated the impact of the C&C product line that was
capable to provide a barrier against allergens and a variety of
different respiratory viruses such as cold, flu and COVID-19.
The first efficacy results are expected within
the next 12 months.
About Medigus
Based in Israel, Medigus Ltd. (Nasdaq: MDGS) is
a technology company focused on innovative growth partnerships,
mainly in advanced medical solutions, digital commerce and electric
vehicle markets. Medigus' affiliations in the medical solutions
arena include ownership in ScoutCam Inc. and Polyzion Ltd. The
Company’s affiliates in digital commerce include Gix Internet Ltd.,
Jeff's Brands Ltd. and Eventer Technologies Ltd. In the electric
vehicle market, Charging Robotics Ltd. and Revoltz Ltd. are also
part of the Company’s portfolio of technology solution providers.
To learn more about Medigus’ advanced technologies, please
visit http://www.medigus.com/.
Forward-Looking Statements
This press release contains forward-looking
statements within the meaning of the “safe harbor” provisions of
the Private Securities Litigation Reform Act of 1995 and other
Federal securities laws. Words such as “expects,” “anticipates,”
“intends,” “plans,” “believes,” “seeks,” “estimates” and similar
expressions or variations of such words are intended to identify
forward-looking statements. For example, Medigus uses
forward-looking statements in this press release when it describes
the medical potential of the PL-14. Because such statements deal
with future events and are based on Medigus’ current expectations,
they are subject to various risks and uncertainties, and actual
results, performance or achievements of Medigus could differ
materially from those described in or implied by the statements in
this press release.
The forward-looking statements contained or
implied in this press release are subject to other risks and
uncertainties, including those discussed in any filings with the
Securities and Exchange Commission (“SEC”). Except as otherwise
required by law, Medigus undertakes no obligation to publicly
release any revisions to these forward-looking statements to
reflect events or circumstances after the date hereof or to reflect
the occurrence of unanticipated events. References and links to
websites have been provided as a convenience, and the information
contained on such websites is not incorporated by reference into
this press release. Medigus is not responsible for the contents of
third-party websites.
Company Contact: Tali DinarChief Financial
Officer+972-8-6466-880ir@medigus.com
Investor Relations Contact:Miri SegalCEOMS-IR
LLC+1-917-607-8654msegal@ms-ir.com
Medigus (NASDAQ:MDGS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Medigus (NASDAQ:MDGS)
Historical Stock Chart
From Sep 2023 to Sep 2024